Entrar Registro gratuito

Adma Biologics Inc Ret. em ativos

Qual é o Ret. em ativos de Adma Biologics Inc?

O Ret. em ativos de Adma Biologics Inc é 9.90%

Qual é a definição de Ret. em ativos?



Retorno sobre os ativos indica como os ativos de uma empresa são lucrativos na geração de receita. É calculado dividindo-se o lucro líquido pelo total de ativos médios.

The return on assets (ROA) tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. It's a useful number for comparing competing companies in the same industry. The number will vary widely across different industries. Return on assets gives an indication of the capital intensity of the company, which will depend on the industry; companies that require large initial investments will generally have lower return on assets. ROAs over 5% are generally considered good.

Ret. em ativos de empresas na Setor Health Care em NASDAQ em comparação com Adma Biologics Inc

O que Adma Biologics Inc faz?

adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.

Empresas com ret. em ativos semelhantes a Adma Biologics Inc